Similar articles

• Hyperkalaemia, ketoacidosis and subcutaneous or intravenous insulin infusions.

  MacRury SM, Small M, MacCuish AC. MacRury SM, et al. Diabetes Res. 1987 Jul;5(3):153-5. Diabetes Res. 1987. PMID: 3117474
• Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.

  Attia N, Jones TW, Holcombe J, Tamborlane WV. Attia N, et al. Diabetes Care. 1998 May;21(5):817-21. doi: 10.2337/diacare.21.5.817. Diabetes Care. 1998. PMID: 9589247 Clinical Trial.
• Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes.

  Tamborlane WV, Sikes KA, Steffen AT, Weinzimer SA. Tamborlane WV, et al. Diabetes Res Clin Pract. 2006 Dec;74 Suppl 2:S112-5. doi: 10.1016/S0168-8227(06)70011-0. Diabetes Res Clin Pract. 2006. PMID: 17182301
• Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy.

  Lenhard MJ, Reeves GD. Lenhard MJ, et al. Arch Intern Med. 2001 Oct 22;161(19):2293-300. doi: 10.1001/archinte.161.19.2293. Arch Intern Med. 2001. PMID: 11606144 Review.
• Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.

  Potti LG, Haines ST. Potti LG, et al. J Am Pharm Assoc (2003). 2009 Jan-Feb;49(1):e1-13; quiz e14-7. doi: 10.1331/JAphA.2009.08122. J Am Pharm Assoc (2003). 2009. PMID: 19196588 Review.